Piper Sandler & Co’s iShares Biotechnology ETF IBB Stock Holding History

Piper Sandler & Co’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-4,800	Closed	-$485K	–	49
2015 Q3	$485K	Buy	+4,800	New	+$576K	0.52%	17

Other funds holding IBB

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Piper Sandler & Co's IBB Position: Q4 2015 in Review

Piper Sandler & Co sold out of iShares Biotechnology ETF (IBB) in Q4 2015, closing a stake of 4,800 shares — an estimated $485K sold.

Piper Sandler & Co first reported a position in IBB in Q3 2015 and held it in 1 quarter. The position peaked at $485K in Q3 2015. 431 funds tracked by Wall St. Rank hold IBB as of Q4 2015.

Piper Sandler & Co reported no remaining iShares Biotechnology ETF position as of Q4 2015 after selling out during the quarter.
Piper Sandler & Co sold 4,800 iShares Biotechnology ETF shares in Q4 2015, an estimated $485K.
Piper Sandler & Co first reported a position in iShares Biotechnology ETF in Q3 2015 and held it in 1 quarter.
Piper Sandler & Co's iShares Biotechnology ETF position peaked at $485K in Q3 2015.
431 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q4 2015.

Based on Piper Sandler & Co's 13F filing for Q4 2015, filed 16 Feb 2016.